Letrozole
Myeloid Leukemia
University Hospital MuensterSmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine M.D. Anderson Cancer Center | Phase 2/3 | BBB |
Cyclophosphamide Actinium Pharmaceuticals | Phase 2/3 | BB |
FILGRASTIM M.D. Anderson Cancer Center | Phase 2 | BB |
5-azacytidine Assistance Publique Hopitaux De Marseille | Phase 3 | B |
Benadryl Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | B |
View all 28 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →